D-0075-2018 Class III Terminated
FDA drug recall D-0075-2018 was initiated by Genzyme Corporation on Oct 12, 2017 and is designated Class III. Reason for recall: Labeling: Incorrect or Missing Package Insert. The recall status is terminated (terminated Sep 10, 2020). Affected quantity: 9,343 single dose vials.
Recall details
- Product Type
- Drugs
- Report Date
- Nov 22, 2017
- Initiation Date
- Oct 12, 2017
- Termination Date
- Sep 10, 2020
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 9,343 single dose vials
Product description
Clolar (clofarabine) 20 mg/20 mL (1 mg/mL) Injection, for intravenous use, Rx Only, Mfd. by: Teva Pharmachemie Swensweg 5 Haarlem, The Netherlands Mfd. for: Genzyme Corporation, Cambridge, MA 02142, NDC 0024-5860-01.
Reason for recall
Labeling: Incorrect or Missing Package Insert.
Distribution pattern
Nationwide
Code information
Lot #: K5006Y01; Exp. 08/31/18 Lot #: K5006Y03; Exp. 08/31/18 Lot #: K6001Y01; Exp. 03/31/19
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0075-2018
- openFDA file date
- Nov 19, 2026
- Loaded by RegDataLab
- Nov 20, 2026
Need the full FDA record for Genzyme Corporation? Ask Claude or ChatGPT with the RegDataLab connector and get every site's inspections, Form 483s, warning letters, recalls and import alerts, each with a link to the FDA source. The API key is free: no card.